What is Zacks Small Cap's Forecast for ABEO FY2025 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities researchers at Zacks Small Cap upped their FY2025 earnings estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, May 19th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings of ($0.64) per share for the year, up from their previous estimate of ($0.74). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

Several other equities research analysts have also commented on ABEO. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Stifel Nicolaus decreased their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective on the stock. Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Finally, HC Wainwright boosted their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Abeona Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $18.50.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO traded down $0.25 during trading on Thursday, hitting $6.17. 585,200 shares of the company were exchanged, compared to its average volume of 1,091,128. The company has a market cap of $315.84 million, a price-to-earnings ratio of -2.30 and a beta of 1.68. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.32. The firm's fifty day moving average price is $5.32 and its 200 day moving average price is $5.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.11.

Insider Buying and Selling

In related news, CEO Vishwas Seshadri sold 25,000 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares of the company's stock, valued at approximately $6,478,439.16. The trade was a 1.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark Alvino sold 8,000 shares of the business's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $5.68, for a total transaction of $45,440.00. Following the completion of the transaction, the director now directly owns 92,435 shares of the company's stock, valued at $525,030.80. The trade was a 7.97% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new position in Abeona Therapeutics in the 4th quarter valued at about $520,000. Trexquant Investment LP acquired a new position in Abeona Therapeutics in the 4th quarter valued at about $382,000. Jane Street Group LLC raised its stake in Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after purchasing an additional 118,262 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 28,606 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in Abeona Therapeutics in the 4th quarter valued at about $362,000. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.